This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oya, M. Articles by Murai, M. Search for Related Content PubMed PubMed Citation Articles by Oya, M. Articles by Murai, M.

Increased Activation of CCAAT/Enhancer Binding Protein-ß Correlates with the Invasiveness of Renal Cell Carcinoma¹

Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan

Positive inflammatory reactions in an aggressive phenotype are typical features of renal cell carcinoma (RCC). Although a high blood level of inflammatory cytokines, such as interleukin-6, interleukin-8, and tumor necrosis factor-, has been observed in these patients, the mechanisms underlying this clinical phenomenon remain to be elucidated. CCAAT/enhancer binding protein (C/EBP) family are transcription factors which play a role in cell differentiation and inflammatory reactions. Among these, C/EBP-ß induces a variety of cytokines and thus may play a role in the pathogenesis of RCC. We studied the activation of C/EBP-ß determined by electrophoretic mobility shift assay in nine RCC cell lines and 44 tissue samples. Six cell lines showed an activation of C/EBP-ß, whereas three cell lines did not, and two of these three had no expression at all of C/EBP-ß protein. Of 44 tissue samples, 12 (27.3%) showed a >200% increase in the activity compared with the corresponding normal kidney tissues. Locally advanced cases had a significantly higher rate of increased C/EBP-ß activity (5 of 8 = 62.5% in advanced cases versus 7 of 36 = 19.4% in localized cases). Especially, all four cases with renal vein invasion had an increased C/EBP-ß activity. These data suggest that the increased activation of C/EBP-ß may contribute to promote tumor invasiveness and render a malignant phenotype of RCC, although it needs to be validated in a larger series.

This article has been cited by other articles:

				T. Schneider-Merck, Y. Pohnke, R. Kempf, M. Christian, J. J. Brosens, and B. Gellersen Physical Interaction and Mutual Transrepression between CCAAT/Enhancer-binding Protein {beta} and the p53 Tumor Suppressor J. Biol. Chem., January 6, 2006; 281(1): 269 - 278. [Abstract] [Full Text] [PDF]

				W. Li, P. Kessler, H. Yeger, J. Alami, A. E. Reeve, R. Heathcott, J. Skeen, and B. R.G. Williams A Gene Expression Signature for Relapse of Primary Wilms Tumors Cancer Res., April 1, 2005; 65(7): 2592 - 2601. [Abstract] [Full Text] [PDF]